CCR2 and metabolic dysfunction-associated steatohepatitis: In mice and humans, infiltration of monocytes and accumulation of MoMF into the chronically injured liver can be inhibited by CCR2/5 antagonists [15,17], while fibroblast growth factor 21 (FGF21) can ameliorate pathogenic drivers of NASH and fibrosis by affecting lipid and glucose metabolism [22,26].